Plasma haloperidol and reduced haloperidol concentrations in a geriatric population

被引:16
作者
Chang, WH
Jann, MW
Chiang, TS
Lin, HN
Hu, WH
Chien, CP
机构
[1] NATL TAIWAN UNIV,COLL MED,DEPT PSYCHIAT,TAIPEI,TAIWAN
[2] TAIPEI MUNICIPAL KWANGTZU PO AI,TAIPEI,TAIWAN
[3] MERCER UNIV,SO SCH PHARM,MACON,GA 31207
关键词
haloperidol; reduced haloperidol; plasma levels; geriatrics; DEBRISOQUINE HYDROXYLATION PHENOTYPE; PHARMACOKINETICS; DISPOSITION;
D O I
10.1159/000119242
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Haloperidol (HL) and reduced haloperidol (RH) plasma concentrations were measured in geriatric patients (n = 45) and schizophrenic patients (n = 8). In the elderly patients, HL doses were 1-4 mg/day while only 2 mg/day was used in the schizophrenics. At HL 2 mg/day dose in both age groups, mean plasma HL levels were approximately twice as high in the elderly patients compared to the schizophrenics(1.39 +/- 0.82 vs. 0.56 +/- 0.23 ng/ml, p < 0.02). RH plasma concentrations were almost 5 times greater in the elderly patients (0.54 +/- 0.35 vs. 0.09 +/- 0.05 ng/ml, p < 0.0001). These results suggest that HL plasma concentrations in the elderly are greater than in adult schizophrenic patients treated with similiar HL doses.
引用
收藏
页码:12 / 16
页数:5
相关论文
共 24 条
[1]   FORMATION OF ACTIVE METABOLITES OF PSYCHOTROPIC-DRUGS - AN UPDATED REVIEW OF THEIR SIGNIFICANCE [J].
CACCIA, S ;
GARATTINI, S .
CLINICAL PHARMACOKINETICS, 1990, 18 (06) :434-459
[2]  
CHANG WH, 1989, BIOL PSYCHIAT, V26, P239
[3]  
CHANG WH, 1989, J CLIN PHARMACOL, V29, P241
[4]   RATIONAL USE OF PSYCHOACTIVE-DRUGS IN THE GERIATRIC-PATIENT [J].
COLEMAN, JH ;
DOREVITCH, AP .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1981, 15 (12) :940-944
[5]  
CRISMON ML, 1990, AM PHARM NS, V30, P757
[6]   CLINICAL PHARMACOKINETIC CONSIDERATIONS IN THE ELDERLY - AN UPDATE [J].
DAWLING, S ;
CROME, P .
CLINICAL PHARMACOKINETICS, 1989, 17 (04) :236-263
[7]  
DYSKEN MW, 1990, CLIN PHARMACOL THER, V47, P162
[8]  
FORSMAN A, 1977, CURR THER RES CLIN E, V21, P245
[9]  
FORSMAN A, 1977, CURR THER RES CLIN E, V21, P396
[10]   PHARMACOKINETICS OF HALOPERIDOL [J].
FROEMMING, JS ;
LAM, YWF ;
JANN, MW ;
DAVIS, CM .
CLINICAL PHARMACOKINETICS, 1989, 17 (06) :396-423